CD38+ CD58− is an independent adverse prognostic factor in paediatric Philadelphia chromosome negative B cell acute lymphoblastic leukaemia patients. (April 2016)

• Record Type: Journal Article
• Authors: Li, Xu-Mian; Zhang, Le-Ping; Wang, Ya-Zhe; Lu, Ai-Dong; Chang, Yan; Zhu, Hong-Hu; Qin, Ya-Zhen; Lai, Yue-Yun; Kong, Yuan; Huang, Xiao-Jun; Liu, Yan-Rong
• Is Part Of: Leukemia research. Volume 43(2016:Apr.)
• Page Start: 33
• Page End: 38
• Publication Date: 2016-04
• Subjects: Paediatric Ph− B-cell acute lymphoblastic leukaemia -- CD38 -- CD58 -- Relapse -- Survival; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2015.12.015
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: Ph− B-ALL patients with CD38+ CD58− have a higher relapse rate and shorter survival. A higher risk population of Ph− B-ALL patients with CD38+ CD58- was identified. A method for better risk stratification was proposed in Ph− B-ALL patients. Abstract: To explore new risk predictors for a high risk of relapse in Philadelphia chromosome negative (Ph−) B cell acute lymphoblastic leukaemia (B-ALL) patients, 196 paediatric Ph− B-ALL patients (≤18 years) were retrospectively analysed. We mainly focus on investigating the prognostic value of CD38 and CD58 expression in leukemic blasts in these patients by four colour flow cytometry. The CD38+ CD58− group ( n = 16) had a higher relapse rate, a shorter 3-year event-free survival (EFS) and overall survival (OS) than the CD38+ CD58+ group ( n = 157; 31.3% vs 10.2%, P = 0.04; 52.4% vs 92.3%, P < 0.01; 32.5% vs 91.0%, P = 0.01); CD38+ CD58− was an independent adverse prognostic predictor for relapse (hazard ratio [HR], 0.203; 95%CI, 0.063–0.656; P = 0.01), 3-year EFS (HR, 0.091; 95%CI, 0.023–0.355; P < 0.01) and OS (HR, 0.102; 95%CI, 0.026–0.3971; P < 0.01) in this cohort, as determined by Cox multivariate analysis. We identified, for the first time, a higher risk population of paediatric Ph− B-ALL patients with CD38+ CD58− who had a higher relapse risk and a shorter survival. Our results may allow better risk stratification and individualized treatment.